ARID2 and hepatocellular carcinoma: In several studies, ARID2 mutations and/or lower protein expression of ARID2 have been reported to correspond to poor patient prognosis in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, breast cancer, oral SCC, and lung cancer47–51.